48,830
edits
Difference between revisions of "Polymorphous adenocarcinoma"
Jump to navigation
Jump to search
Polymorphous adenocarcinoma (view source)
Revision as of 20:12, 25 February 2021
, 20:12, 25 February 2021→IHC
(→IHC) |
(→IHC) |
||
| Line 74: | Line 74: | ||
*Vimentin +ve. | *Vimentin +ve. | ||
*p40 -ve (22 of 23 cases<ref name=pmid31653135>{{cite journal |authors=Atiq A, Mushtaq S, Hassan U, Loya A, Hussain M, Akhter N |title=Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma |journal=Asian Pac J Cancer Prev |volume=20 |issue=10 |pages=2917–2921 |date=October 2019 |pmid=31653135 |pmc=6982655 |doi=10.31557/APJCP.2019.20.10.2917 |url=}}</ref>). | *p40 -ve (22 of 23 cases<ref name=pmid31653135>{{cite journal |authors=Atiq A, Mushtaq S, Hassan U, Loya A, Hussain M, Akhter N |title=Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma |journal=Asian Pac J Cancer Prev |volume=20 |issue=10 |pages=2917–2921 |date=October 2019 |pmid=31653135 |pmc=6982655 |doi=10.31557/APJCP.2019.20.10.2917 |url=}}</ref>). | ||
**Useful to | **Useful to differentiate from [[adenoid cystic carcinoma]] (AdCC); AdCC is usually p63 +ve/p40 +ve (36 or 47 cases) or p63 -ve/p40 -ve (10 of 47 cases). | ||
*p63 +ve (22 of 23 cases<ref name=pmid31653135/>). | *p63 +ve (22 of 23 cases<ref name=pmid31653135/>). | ||